Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer - PubMed (original) (raw)
. 2003 May 1;63(9):2306-11.
Affiliations
- PMID: 12727854
Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer
Sadmeet Singh et al. Cancer Res. 2003.
Abstract
The androgen-sensitive LNCaP prostate cancer cell line is less invasive than hormone-insensitive lines. CL1, an aggressive, hormone-insensitive LNCaP subline derived by continuous passaging in hormone-depleted medium, was compared with the parental cell line by cDNA microarray analysis. The gene coding for the intermediate filament protein vimentin was found to be highly up-regulated in the CL1 subline. This difference was confirmed by Northern and Western blots and visualized by immunofluorescence microscopy. To assess the contribution of vimentin to the invasive phenotype, LNCaP cells were stably transfected to overexpress vimentin, and the CL1 cells were transfected with vimentin antisense construct. The invasiveness of the transfected cells was tested using an in vitro invasion assay. We were able to demonstrate that decreasing vimentin expression in the constitutively vimentin-expressing CL1 cells led to a significant decrease in their invasiveness but that forcing expression of vimentin in the LNCaP cells did not augment their invasiveness. These findings imply that vimentin expression contributes to the invasive phenotype but cannot confer it alone.
Similar articles
- Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A. Tso CL, et al. Cancer J. 2000 Jul-Aug;6(4):220-33. Cancer J. 2000. PMID: 11038142 - [Effect of PC-1 gene expression on migration ability of prostate cancer cells].
Zhang H, Wan LC, Wang J, Zhou JG, Huang CF. Zhang H, et al. Ai Zheng. 2005 Sep;24(9):1043-7. Ai Zheng. 2005. PMID: 16159422 Chinese. - Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS. Freedland SJ, et al. Prostate. 2003 Jun 1;55(4):299-307. doi: 10.1002/pros.10226. Prostate. 2003. PMID: 12712409 - Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS. Freedland SJ, et al. Prostate. 2003 Apr 1;55(1):71-80. doi: 10.1002/pros.10202. Prostate. 2003. PMID: 12640663 - Coexpression of cytokeratin and vimentin.
McGuire LJ, Ng JP, Lee JC. McGuire LJ, et al. Appl Pathol. 1989;7(2):73-84. Appl Pathol. 1989. PMID: 2471541 Review.
Cited by
- p21-Activated Kinases in Thyroid Cancer.
Bautista L, Knippler CM, Ringel MD. Bautista L, et al. Endocrinology. 2020 Aug 1;161(8):bqaa105. doi: 10.1210/endocr/bqaa105. Endocrinology. 2020. PMID: 32609833 Free PMC article. Review. - A Multiplex Test Assessing _MiR663a_me and _VIM_me in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions.
Monteiro-Reis S, Blanca A, Tedim-Moreira J, Carneiro I, Montezuma D, Monteiro P, Oliveira J, Antunes L, Henrique R, Lopez-Beltran A, Jerónimo C. Monteiro-Reis S, et al. J Clin Med. 2020 Feb 24;9(2):605. doi: 10.3390/jcm9020605. J Clin Med. 2020. PMID: 32102337 Free PMC article. - Cooperation therapy between anti-growth by photodynamic-AIEgens and anti-metastasis by small molecule inhibitors in ovarian cancer.
Dai J, Xu M, Wang Q, Yang J, Zhang J, Cui P, Wang W, Lou X, Xia F, Wang S. Dai J, et al. Theranostics. 2020 Jan 16;10(5):2385-2398. doi: 10.7150/thno.41708. eCollection 2020. Theranostics. 2020. PMID: 32104509 Free PMC article. - The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin.
Bargagna-Mohan P, Hamza A, Kim YE, Khuan Abby Ho Y, Mor-Vaknin N, Wendschlag N, Liu J, Evans RM, Markovitz DM, Zhan CG, Kim KB, Mohan R. Bargagna-Mohan P, et al. Chem Biol. 2007 Jun;14(6):623-34. doi: 10.1016/j.chembiol.2007.04.010. Chem Biol. 2007. PMID: 17584610 Free PMC article. - Vimentin epigenetic deregulation in Bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition.
Monteiro-Reis S, Miranda-Gonçalves V, Guimarães-Teixeira C, Martins-Lima C, Lobo J, Montezuma D, Dias PC, Neyret-Kahn H, Bernard-Pierrot I, Henrique R, Jerónimo C. Monteiro-Reis S, et al. Int J Biol Sci. 2023 Jan 1;19(1):1-12. doi: 10.7150/ijbs.77181. eCollection 2023. Int J Biol Sci. 2023. PMID: 36594099 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical